- Alnylam Pharmaceuticals (ALNY) is out with 5X15 pipeline goals.
- The company says it now plans to have "six to seven genetic medicine programs in the clinic, including at least two programs in Phase 3 and five to six programs that will have achieved human proof-of-concept results supporting further development," by the end of 2015.
- 2014 expectations: Enrollment in APOLLO (patisiran) and collection of "key clinical endpoint data" from Phase 2 extension study with results due late in the year; initiation of ALNY's second Phase 3 study (ALN-TTRsc in the cardiac amyloidosis) and data from a Phase 2 trial of ALN-TTRsc by year end; ALN-AT3 (hemophilia) set to start Phase 1.
- FY13 year end cash guidance: $350M. (PR)
Alnylam Pharma gives pipeline update
Jan 10 2014, 16:19 ET